We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay
News

Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay

Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay
News

Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sequenom, Inc. has announced that its non-invasive fetal Rhesus D (RHD) genotyping assay demonstrated 100% concordance with routine European non-invasive Real-time PCR (RT-PCR) methods.

This data demonstrates that the research use only fetal RHD genotyping assay utilizing Sequenom's MassARRAY® technology may be a suitable alternative for clinical assessment of prenatal RHD incompatibility.

“Clinical concordance between the MassARRAY platform and the current standards employed in the European community is an important validation of our testing approach,” stated Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom.

“Our first clinical licensee Lenetix Medical Screening Laboratory, Inc. is scheduled to launch its 'home brew' application for RHD incompatibility on a RT-PCR platform this quarter and we expect a 'home brew' RHD incompatibility test on the MassARRAY platform to be introduced later this year through a CLIA-certified laboratory. We plan to continue developing non-invasive prenatal tests for other genetic markers,” Stylli said.

Preliminary studies performed by Sequenom in collaboration with Professor Tobias Legler at University Goettingen compared Sequenom's MassARRAY technology with RT-PCR for fetal RHD genotyping.

In Europe, fetal RHD genotyping by RT-PCR is routinely performed for high risk pregnancies. The Sequenom studies utilized samples collected from 100 pregnant women between 13 and 39 weeks of pregnancy (mean gestational age 26 weeks). Whole blood from each patient was processed into a plasma sample and a cellular blood component sample for fetal and maternal RHD genotyping, respectively.

RHD genotypes for maternal and fetal RHD samples generated by the MassARRAY platform were compared to the results obtained from RT-PCR. Each RHD genotype result generated by the MassARRAY platform matched the RT-PCR result obtained for the same sample--establishing 100% concordance between assay results. Overall sensitivity for both methods was 100%, with 98% specificity.

Advertisement